

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IFW
CD

Applicant: Jeremy Clark
Serial No.: 10/828,753
Filed: April 21, 2004
Title: Modified Fluorinated Nucleoside Analogues


Examiner: Not Yet Assigned
Group Art Unit: 1614
Docket: 60137.002USU1

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 on June 9, 2005.

By:
Name: Joseph Bennett-Paris

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450



23552

PATENT TRADEMARK OFFICE

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Supplemental Information Disclosure Statement, Form 1449
- ☒ CD in duplicate containing Foreign Patent Documents; "Other" cited Art (23)
- ☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

Merchant & Gould P.C.
P.O. Box 2903
Minneapolis, MN 55402-0903
612.332.5300

By:
Name: Joseph Bennett-Paris
Reg. No.: 47,226
JBP



S/N 10/828,753


PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Jeremy Clark	Examiner:	Not yet assigned
Serial No.:	10/828,753	Group Art Unit:	1614
Filed:	April 21, 2004	Docket No.:	60137.002USU1
Title:	Modified Fluorinated Nucleoside Analogues		

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Mail Stop AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 9, 2005.

By: 
Name: Joseph Bennett-Paris

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

Because this application was filed after June 30, 2003, a CD in duplicate has been provided only for the foreign patent documents and copies of "Other documents" listed on the enclosed Form 1449.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.


Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, MN 55402-0903
(404) 954/5044

Date: June 9, 2005



Joseph Bennett-Paris
Reg. No. 47,226



FORM PTO 149* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 60137.0002USU1	Application Number: 10/828,753
	Applicant: Jeremy Clark	
	Filing Date: April 21, 2004	Group Art Unit:

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	3,798,209	03/19/1974	Witkowski et al.			
	4,957,924	09/18/1990	Beauchamp			
	5,026,687	06/25/1991	Yarchoan et al.			
	5,149,794	09/22/1992	Yatvin et al.			
	5,157,027	10/20/1992	Biller et al.			
	5,194,654	03/16/1993	Hostetler et al.			
	5,223,263	06/29/1993	Hostetler et al.			
	5,256,641	10/26/1993	Yatvin et al.			
	5,372,808	12/13/1994	Blatt et al.			
	5,411,947	05/02/1995	Hostetler et al.			
	5,463,092	10/31/1995	Hostetler et al.			
	5,496,546	03/05/1996	Wang et al.			
	5,538,865	07/23/1996	Reyes et al.			
	5,543,389	08/06/1996	Yatvin et al.			
	5,543,390	08/06/1996	Yatvin et al.			
	5,543,391	08/06/1996	Yatvin et al.			
	5,554,728	09/10/1996	Basava et al.			
	5,610,054	03/11/1997	Draper			
	5,633,358	05/27/1997	Gruetzke et al.			
	5,633,388	05/27/1997	Diana et al.			
	5,676,942	10/14/1997	Testa et al.			
	5,711,944	01/27/1998	Gilbert et al.			
	5,725,859	03/10/1998	Omer			
	5,738,845	04/14/1998	Imakawa			
	5,738,846	04/14/1998	Greenwald et al.			
	5,747,646	05/05/1998	Hakimi et al.			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 60137.0002USU1	Application Number: 10/828,753
	Applicant: Jeremy Clark	
	Filing Date: April 21, 2004	Group Art Unit:

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,792,834	08/11/1998	Hakimi et al.			
	5,830,905	11/03/1998	Diana et al.			
	5,830,455	11/03/1998	Valtuna et al.			
	5,834,594	11/10/1998	Hakimi et al.			
	5,837,257	11/17/1998	Tsai et al.			
	5,846,964	12/08/1998	Ozeki			
	5,849,696	12/15/1998	Chretien et al.			
	5,869,253	02/09/1999	Draper			
	5,891,874	04/06/1999	Colacino et al.			
	5,905,070	05/18/1999	Schinazi et al.			
	5,908,621	06/01/1999	Glue et al.			
	5,922,757	07/13/1999	Chojkier			
	5,928,636	07/27/1999	Alber et al.			
	5,942,223	08/24/1999	Bazer et al.			
	5,980,884	11/09/1999	Blatt et al.			
	5,990,276	11/23/1999	Zhang et al.			
	6,004,933	12/21/1999	Spruce et al.			
	6,034,134	03/07/2000	Gold et al.			
	6,043,077	03/28/2000	Barber et al.			
	6,056,961	05/02/2000	Lavie et al.			
	6,348,587 B1	02/19/2002	Schinazi et al.			
	2002/0058635	05/16/2002	Averett			
	6,410,531	06/25/2002	Llinas-Brunet et al.			
	6,420,380	07/16/2002	Llinas-Brunet et al.			
	2003/0050229	03/13/2003	Sommadosi et al.			
	6,534,523	03/18/2003	Llinas-Brunet et al.			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 60137.0002USU1	Application Number: 10/828,753
	Applicant: Jeremy Clark	
	Filing Date: April 21, 2004	Group Art Unit:

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	6,660,721	12/09/2003	Devos et al.				
	6,680,303	01/20/2004	Schinazi et al.				
	2004/0023240	02/05/2004	Marliere et al.				
	2004/0067901	04/08/2004	Bhat et al.				
	2004/0072788	04/15/2004	Bhat et al.				
	2004/0110717	06/10/2004	Carroll et al.				
	6,777,395	08/17/2004	Bhat et al.				
	2004/0214844	10/28/2004	Otto et al.				
	2004/0254141	12/16/2004	Schinazi et al.				
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	199 14 474	10/07/1999	DE				
	0 350 287	01/10/1990	EP				
	0 180 276	05/07/1996	EP				
	WO 89/02733	04/06/1989	PCT				
	WO 90/00555	01/25/1990	PCT				
	WO 91/16920	11/14/1991	PCT				
	WO 91/18914	12/12/1991	PCT				
	WO 91/19721	12/26/1991	PCT				
	WO 93/00910	01/21/1993	PCT				
	WO 94/26273	11/24/1994	PCT				
	WO 95/13090	05/18/1995	PCT				
	WO 96/15132	05/23/1996	PCT				
	WO 97/36554	10/09/1997	PCT				

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 60137.0002USU1	Application Number: 10/828,753
	Applicant: Jeremy Clark	
	Filing Date: April 21, 2004	Group Art Unit:

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 98/17679	04/30/1998	PCT				
	WO 98/22496	05/28/1998	PCT				
	WO 99/07734	02/18/1999	PCT				
	WO 99/15194	04/01/1999	PCT				
	WO 99/32139	07/01/1999	PCT				
	WO 99/32140	07/01/1999	PCT				
	WO 99/43691	09/02/1999	PCT				
	WO 99/59621	11/25/1999	PCT				
	WO 99/64016	12/16/1999	PCT				
	WO 00/09531	02/24/2000	PCT				
	WO 00/24355	05/04/2000	PCT				
	WO 00/37110	06/29/2000	PCT				
	WO 01/32153	05/10/2001	PCT				
	WO 01/60315	08/23/2001	PCT				
	WO 01/079246	10/25/2001	PCT				
	WO 01/81359	11/01/2001	PCT				
	WO 01/90121	11/29/2001	PCT				
	WO 01/91737	12/06/2001	PCT				
	WO 01/92282	12/06/2001	PCT				
	WO 01/96353	12/20/2001	PCT				
	WO 02/008251	01/31/2002	PCT				
	WO 02/008256	01/31/2002	PCT				
	WO 02/057287	07/25/2002	PCT				
	WO 02/057425	07/25/2002	PCT				
	WO 02/060926	08/08/2002	PCT				

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 60137.0002USU1	Application Number: 10/828,753
	Applicant: Jeremy Clark	
	Filing Date: April 21, 2004	Group Art Unit:

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 02/008187	01/31/2002	PCT				
	WO 02/08198	01/31/2002	PCT				
	WO 02/18404	03/07/2002	PCT				
	WO 02/032414	04/25/2002	PCT				
	WO 02/32920	04/25/2002	PCT				
	WO 02/48116	06/20/2002	PCT				
	WO 02/048157	06/20/2002	PCT				
	WO 02/48165	06/20/2002	PCT				
	WO 02/48172	06/20/2002	PCT				
	WO 02/100415	12/19/2002	PCT				
	WO 03/024461	03/27/2003	PCT				
	WO 03/105770	12/24/2003	PCT				
	WO 03/061576	07/31/2003	PCT				
	WO 2004/000858	12/31/2003	PCT				
	WO 2004/002422	01/08/2004	PCT				
	WO 2004/002999	01/08/2004	PCT				
	WO 2004/003000	01/08/2004	PCT				
	WO 2004/003138	01/08/2004	PCT				
	WO 2004/007512	01/22/2004	PCT				
	WO 2004/009020	01/29/2004	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Identifier	
A	BATTAGLIA, A.M. et al., Ann. Pharmacother. 34:487-494, 2000.
B	BHAT et al., (Oral Session V, Hepatitis C Virus, Flaviviridae; 16 th International Conference on Antiviral Research (Apr. 27, 2003, Savannah, GA)); p A75.
C	CHU, M., et al., Bioorganic and Medicinal Chemistry Letters 9:1949-1952.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 60137.0002USU1	Application Number: 10/828,753
	Applicant: Jeremy Clark	
	Filing Date: April 21, 2004	Group Art Unit:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	Identifier	
	D	DELAMBERT et al., J. Med. Chem., 1994, 37:498.
	E	ELDRUP et al., (Oral Session V, Hepatitis C Virus, Flaviviridae; 16 th International Conference on Antiviral Research (Apr. 27, 2003, Savannah, GA))
	F	Eldrup, A. et al., "Structure-Activity Relationship of Purine Ribonucleosides for Inhibition of Hepatitis C Virus RNA-Dependent RNA Polymerase," <i>J. Med. Chem.</i> , Vol. 47, pp. 2283-2295 (2004)
	G	FARQUHAR et al., J. Med. Chem., 1983, 26:1153.
	H	FARQUHAR et al., J. Med. Chem., 1985, 28:1358.
	I	FREED et al., Biochem. Pharmacol., 1989, 38:3193.
	J	HOSETLER, K.Y. et al., "Synthesis and antiretro-viral activity of phospholipids analogs of azidothymidine and other antiviral nucleosides," 1990, J. Biol. Chem., 265:61127.
	K	HOSTELLER, K.Y. et al., "Greatly enhanced inhibition of human immunodeficiency virus type 1 replication in CEM and HT4-6 cells by 3'-dideoxythymidine diphosphate dimyristoylglycerol, a lipid prodrug of 3'-dideoxythymidine," 1992, Antimicrob. Agents Chemother., 36:2025-2029.
	L	HUNSTON et al., J. Med. Chem., 1984, 27:440-444.
	M	JONES, R. and BISEHOFFERGER, N., Antiviral Research, 1995, 27:1-17.
	N	KHANINEI and TORRENCE, J. Med. Chem., 1996, 39:4109-4115.
	O	KUCERA, L.S. et al., "Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation," 1990, AIDS Hum. Retro. Viruses, 6:491-501.
	P	MEIER et al., Bioorg. Med. Chem. Lett., 1997, 7:99-104.
	Q	OLSEN et al., (Oral Session V, Hepatitis C Virus, Flaviviridae; 16 th International Conference on Antiviral Research (Apr. 27, 2003, Savannah, GA)); p A76.
	R	PIANTADOSI, C. et al., "Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV activity," 1991, J. Med. Chem. 34:1408-1414.
	S	STARRETT et al., J. Med. Chem., 1994, 37:1857-1864.
	T	STUYVER et al. Journal of Virology, 2003, 77, 10689-10694.
	U	STUYVER et al., "Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture," Antimicrobial Agents and Chemotherapy, 2003, 47:244-254.
	V	Stuyver, L. et al., "Inhibition of the Subgenomic Hepatitis C Virus Replicon in Huh-7 Cells by 2'-Deoxy-2'-fluorocytidine," <i>Antimicrob. Agents Chemother.</i> , Vol. 48, No. 2, pp. 651-654 (February 2004)
	W	ZON, Progress in Med. Chem., 1982, 19:205-246.

EXAMINER	DATE CONSIDERED	23552 PATENT TRADEMARK OFFICE
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.		